[How safe is the recombinant human growth hormone?]

Area of Science:

• Biotechnology and Pharmacology
• Endocrinology

Background:

• Biosynthetic human growth hormone (bhGH) is a critical therapeutic agent.
• Ensuring the safety of bhGH involves rigorous evaluation throughout its lifecycle.

Purpose of the Study:

• To comprehensively review the safety aspects of biosynthetic human growth hormone.
• To outline the regulatory pathway for bhGH safety verification in Mexico.

Main Methods:

• Literature review of safety data and regulatory requirements.
• Analysis of evidence linking bhGH use to various adverse events.
• Examination of safety considerations including dosing and long-term outcomes.

Main Results:

• bhGH is classified as a biosynthetic drug requiring phased safety evaluations.
• Evidence reviewed for associations with intracranial hypertension, musculoskeletal events, metabolic risks, and cancer.
• Safety data covers preclinical, clinical, and observational studies.

Conclusions:

• Thorough safety assessment is crucial for biosynthetic human growth hormone.
• Understanding potential adverse events informs clinical practice and regulatory oversight.
• Phased safety evaluations, from obtaining to observational studies, are essential for bhGH in Mexico.